Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Charit\u00e9 Universit\u00e4tsmedizin","sponsor":"Actimed Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Actimed Therapeutics Licenses Additional European Patent Rights to S-oxprenolol in ALS from Charit\u00e9 - Universit\u00e4tsmedizin Berlin","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical"},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Faraday Pharmaceuticals","pharmaFlowCategory":"D","amount":"$134.7 million","upfrontCash":"$2.7 million","newsHeadline":"Actimed Therapeutics and Faraday Pharmaceuticals Announce License Agreement for S-oxprenolol","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical"},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Actimed Therapeutics Granted Broad US Patent Covering Rights to ACM\u2013002 (S-oxprenolol) for Treating Cancer Cachexia","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals for MolPort-001-770-529

    Menu

    MolPort-001-770-529

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    GLOBAL SALES INFORMATION

    ANALYTICAL SOLUTION(s)

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Actimed Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Actimed Therapeutics and Faraday Pharmaceuticals Announce License Agreement for S-oxprenolol

              Details:

              Faraday gains global rights to develop and commercialize S-oxprenolol for cancer cachexia and any other indications outside of amyotrophic lateral sclerosis (ALS).

              Lead Product(s): Oxprenolol

              Therapeutic Area: Nutrition and Weight Loss Product Name: ACM-002

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Faraday Pharmaceuticals

              Deal Size: $134.7 million Upfront Cash: $2.7 million

              Deal Type: Licensing Agreement April 13, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Actimed Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Actimed Therapeutics Granted Broad US Patent Covering Rights to ACM–002 (S-oxprenolol) for Treating Cancer Cachexia

              Details:

              ACM-002 (S-oxprenolol) is the second in a new class of anabolic-catabolic transforming agents (ACTAs) under development by Actimed. The new patent contains claims which cover the treatment of the symptoms of cachexia in patients having a late stage cancer.

              Lead Product(s): Oxprenolol

              Therapeutic Area: Nutrition and Weight Loss Product Name: ACM-002

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 01, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Charité Universitätsmedizin

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Country
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Actimed Therapeutics Licenses Additional European Patent Rights to S-oxprenolol in ALS from Charité - Universitätsmedizin Berlin

              Details:

              Actimed Therapeutics has licensed additional European patent rights to S-oxprenolol in amyotrophic lateral sclerosis (ALS) from Charité – Universitätsmedizin Berlin (Charité). This gives Actimed global rights in this indication.

              Lead Product(s): Oxprenolol

              Therapeutic Area: Neurology Product Name: ACM-002

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Actimed Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement November 23, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.
              Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.
              Post Enquiry
              POST ENQUIRY